Back
Is ticagrelor worth its high cost and side-effects?
Journal article

Is ticagrelor worth its high cost and side-effects?

  • Guerbaai RA a Departement Public Health (DPH), Faculty of Medicine , University of Basel , Basel , Switzerland.
  • Mahata I b Tulane School of Medicine , Tulane Heart and Vascular Institute , New Orleans , LA , USA.
  • Maréchaux S c GCS-Groupement des Hôpitaux de l'Institut Catholique de Lille, Hôpital Saint Philibert, Faculty of Medicine and Maieutics, Catholic University of Lille , Lille , France.
  • Le Jemtel TH b Tulane School of Medicine , Tulane Heart and Vascular Institute , New Orleans , LA , USA.
  • Ennezat PV d Department of Cardiology , Centre Hospitalier Regional Universitaire Grenoble-Alpes , La Tronche , France.
Show more…
  • 2018-05-08
Published in:
  • Acta cardiologica. - 2019
Cardiovascular disease
dyspnoea
side effects
ticagrelor
Acute Coronary Syndrome
Drug Costs
Drug-Related Side Effects and Adverse Reactions
Global Health
Humans
Incidence
Purinergic P2Y Receptor Antagonists
Ticagrelor
English Ticagrelor is a reversible P2Y12 receptor antagonist that is more potent than clopidogrel. When used in combination with aspirin, it reduces cardiovascular events in patients with acute coronary syndrome. However, unbiased review of 5 randomised controlled trials indicates that although statistically significant, the clinical superiority of ticagrelor over clopidogrel is modest. Thus, identification of patients who benefit the most from ticagrelor is a priority. Besides bleeding issues, ticagrelor can frequently cause bouts of dyspnoea, which requires ticagrelor replacement by another P2Y12 receptor antagonist, with a loading dose.
Language
  • English
Open access status
closed
Identifiers
Persistent URL
https://sonar.ch/global/documents/92468
Statistics
Document views: 14 File downloads: